ORCA (ORCA) fluctuates 91.4% within 24 hours: Regulatory announcement triggers short squeeze and Solana DEX trading volume surge
Bitget Pulse2026/04/26 22:03Brief Overview of Volatility
In the past 24 hours, ORCA's price surged from a low of $1.101 to a high of $2.107, with an amplitude of 91.4%, and is currently quoted at $1.369. The 24-hour trading volume skyrocketed to approximately $552 million–$596 million, with Orca DEX's own trading volume reaching $95.76 million (accounting for 21.3% of Solana DEX total volume), fees at $92,022, and capital flows indicating a net inflow signal.
Brief Analysis of the Cause of Abnormal Movement
- Regulatory Announcement: ORCA has joined over 120 entities (including Blockchain Association) to jointly promote U.S. crypto market structure legislation, and news within this 24-hour period directly triggered a 40%-78% price surge.
- Short Squeeze: Funding rates turned negative and opening interest surged, resulting in large-scale short covering, pushing the price to rebound from a low of $0.941 to $1.621.
- On-chain and Ecosystem Drivers: Solana DEX overall trading volume exploded, Orca platform’s 24-hour trading volume exceeded $95 million, fees reached $105,000, and TVL stands at $236 million, benefiting from high-frequency trading and concentrated liquidity advantages within the ecosystem.
Market Views and Outlook
Community sentiment is 85% bullish, seeing the abnormal move as a daily breakout opportunity, but mainstream opinions highlight high volatility risk and suggest waiting for a pullback to the $0.94–$1.10 support level, advising against chasing highs. Discussions on X platform point out that unusual trading volume (48 times normal levels) could trigger rapid corrections, with clear signs of accumulation. Analysts note that regulatory tailwinds may attract institutions, but the likelihood of a short-term cooling-off period after the surge is high. Pay attention to the sustainability of trading volume and the $1.50–$1.55 support zone.
Note: This analysis is automatically generated by AI based on public data and on-chain monitoring, and is for informational reference only.Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
U.S. non-farm payrolls surge by 165,000 in October, far exceeding expectations! Unemployment rate unexpectedly drops to 4.1%, December rate hike expectations intensify
In October, US non-farm payrolls increased by 165,000, which is 2.5 times the Wall Street median forecast of 65,000 and represents an exceptionally strong deviation of about 5 standard deviations, exceeding the upper limit of all institutional forecast ranges. The unemployment rate unexpectedly fell from 4.2% to 4.1%, while the market had expected it to remain unchanged; average hourly wages also accelerated year-on-year growth to 3.1%. Meanwhile, the previous two months' non-farm payrolls were revised upwards by a total of 84,000. Following the release of the data, the yield on 2-year US Treasury bonds rose by 7 basis points, and the pricing of the probability of a Fed rate hike in December climbed to 70%.
AI Sell-off Hits Anthropic IPO, Potential Valuation Expected to Drop to $1.2–1.3 Trillion
The valuation range discussed by potential investors has been lowered from the previous high of $2 trillion to between $1.2 trillion and $1.3 trillion, and some strategists have even suggested going below $1 trillion to ensure safety. In the face of significant market volatility and financial concerns such as quarterly losses, Anthropic is facing tough decisions, including a discounted valuation, reducing the size of the offering, or postponing the listing.
Moderna Q3 revenue up 29% year-on-year, far exceeding expectations, raises full-year revenue growth guidance to 15%-25% | Earnings Report Insight
Moderna's Q3 revenue increased by 29% year-on-year to $1.31 billion, with profits significantly exceeding expectations. The company raised its 2026 revenue growth guidance to 15%-25%. The ramp-up of next-generation COVID-19 and flu vaccines, along with international market expansion, has driven performance improvement. Phase III data for the personalized cancer vaccine has also shown positive progress. The company is simultaneously advancing cost reduction and pipeline R&D, with year-end cash expectations significantly raised.
Crypto prices
More
